Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

181. Francica JR, Zak DE, Linde C, et al. Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. Blood Adv. 2017;1(25):2329-2342. Full Text available with Trip Pro

Francica JR, Zak DE, Linde C, et al. Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. Blood Adv. 2017;1(25):2329-2342. 29507074 2018 10 25 2473-9537 2 5 2018 03 13 Blood advances Blood Adv Francica JR, Zak DE, Linde C, et al. Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. Blood Adv . 2017;1(25):2329-2342. 516 10.1182/bloodadvances.2018017491 eng

2018 Blood advances

182. Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (Genvoya) - human immunodeficiency virus-1 (HIV-1)

Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (Genvoya) - human immunodeficiency virus-1 (HIV-1) Published 12 March 2018 Statement of Advice: elvitegravir 150mg / cobicistat 150mg / emtricitabine 200mg / tenofovir alafenamide 10mg (Genvoya ® ) SMC No 1323/18 Gilead Sciences Ltd 9 February 2018 ADVICE: in the absence of a submission from the holder of the marketing authorisation elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (Genvoya ® ) is not recommended (...) for use within NHS Scotland. Indication under review: Treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot

2018 Scottish Medicines Consortium

183. Efavirenz/Emtricitabine/Tenofovir disoproxil - HIV

Environmental Risk Assessment GC-HS Gas Chromatography head space HDPE High Density Polyethylene HIV Human Immunodeficiency Virus HBV Hepatitis B Virus HPLC High performance liquid chromatography ICH International Conference on Harmonisation of Technical Requirements IR Infrared KF Karl Fischer titration LDPE Low Density Polyethylene Ph. Eur. European Pharmacopoeia RMP Risk Management Plan T max Time of maximum observed plasma concentration; if it occurs at more than one time point, Tmax was defined (...) Krka is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of 5 times the ULN, intenuption or discontinuation of treatment must be considered. • Advice to monitor the liver enzymes of patients treated with other medicinal products associated with liver toxicity. • Warning that reports of hepatic failure have

2018 European Medicines Agency - EPARs

184. Lopinavir/ritonavir (Kaletra) - human immunodeficiency virus (HIV-1) infected children aged from 14 days to less than 2 years old.

Lopinavir/ritonavir (Kaletra) - human immunodeficiency virus (HIV-1) infected children aged from 14 days to less than 2 years old. Lopinavir/ritonavir (Kaletra ® ). Reference number 3557 Page 1 of 3 Enc 7 Appx 2 AWMSG Secretariat Assessment Report – Limited submission Lopinavir/ritonavir (Kaletra ® ) 80 mg/20 mg oral solution Company: AbbVie Ltd. Licensed indication under consideration: In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (...) antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to less than 2 years old. Lopinavir/ritonavir oral solution is already licensed for use in patients aged 2 years and over in the same indication and is included on Welsh health board formularies. Marketing authorisation for this older age group was granted before 1 October 2010, and was not appraised by the All Wales Medicines Strategy Group (AWMSG) as it did not meet the criteria

2018 All Wales Medicines Strategy Group

185. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza) - Human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza) - Human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza ® ). Reference number 2418. Page 1 of 3 Enc 9 Appx 2 AWMSG Secretariat Assessment Report – Limited submission Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza ®? ) 800 mg/150 mg/200 mg/10 mg film-coated tablet Company: Janssen-Cilag Ltd Licensed indication under (...) consideration: Treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg). ? This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Marketing authorisation date: 26 September 2017 Comparator(s) ? Darunavir/cobicistat (Rezolsta ® ) in combination with emtricitabine

2018 All Wales Medicines Strategy Group

186. mCME project V.2.0: randomised controlled trial of a revised SMS-based continuing medical education intervention among HIV clinicians in Vietnam Full Text available with Trip Pro

mCME project V.2.0: randomised controlled trial of a revised SMS-based continuing medical education intervention among HIV clinicians in Vietnam Continuing medical education (CME) is indispensable, but costs are a barrier. We tested the effectiveness of a novel mHealth intervention (mCME V.2.0) promoting CME among Vietnamese HIV clinicians.We enrolled HIV clinicians from three provinces near Hanoi. The 6-month intervention consisted of (1) daily short message service multiple-choice quiz (...) questions, (2) daily linked readings, (3) links to online CME courses and (4) feedback messages describing the performance of the participant relative to the group. Control participants had equal access to the online CME courses. Our primary endpoint was utilisation of the online CME courses; secondary endpoints were self-study behaviour, performance on a standardised medical exam and job satisfaction.From 121 total HIV clinicians in the three provinces, 106 (87.6%) enrolled, and 48/53 intervention (90

2018 BMJ global health Controlled trial quality: predicted high

187. Zinc, copper, CD4 T-cell count and some hematological parameters of HIV-infected subjects in Southern Nigeria Full Text available with Trip Pro

Zinc, copper, CD4 T-cell count and some hematological parameters of HIV-infected subjects in Southern Nigeria Low concentration of trace elements has been associated with poor prognosis and mortality in HIV infection.A cross sectional study was conducted among 100 HIV-infected subjects (70 were on ART treatment, while 30 were ART naïve). Fifty (50) apparently healthy controls were enrolled. Concentration of serum levels of zinc and copper was done using atomic absorption spectrometric method (...) , while complete blood count was determined using automated blood analyzer. CD4+ T-cell count was done using cyflow cytometer.The aim of this study was to investigate the level of some trace elements and some hematological parameters of HIV-seropositive subjects attending University of Calabar Teaching Hospital Clinic as well as prevalence of trace elements deficiency and anemic status and compare same with HIV-seronegative control.Mean serum zinc, CD4+ T-cell count, Hb, PCV, RBC, MXD, were

2018 Integrative medicine research

188. Cross-country Association of Press Freedom and LGBT freedom with prevalence of persons living with HIV: implication for global strategy against HIV/AIDS Full Text available with Trip Pro

Cross-country Association of Press Freedom and LGBT freedom with prevalence of persons living with HIV: implication for global strategy against HIV/AIDS Human behaviors are affected by attitudes and beliefs, which in turn are shaped by higher-level values to which we have ascribed. In this study, we explore the relationship between two higher-level values, press freedom and LGBT freedom, and HIV infection with national data at the population level.Data were the number of persons living with HIV (...) during 2011-15 was 0.51 per 1000 population. The prevalence showed a geographic pattern moving from high at the south and west ends of the world map to low at the north and east. Both PFI and LGBT-FI were positively associated with PLWH prevalence with a negative interaction between the two.More people are infected with HIV in countries with higher press freedom and higher LGBT freedom. Furthermore, press freedom can attenuate the positive association between levels of LGBT freedom and risk of HIV

2018 Global health research and policy

189. HIV/AIDS and older adults in Cameroon: Emerging issues and implications for caregiving and policy-making Full Text available with Trip Pro

HIV/AIDS and older adults in Cameroon: Emerging issues and implications for caregiving and policy-making The burden of human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS) on the elderly population in three divisions within the Northwest Region of Cameroon was examined. Data for this paper were extracted from a larger study which had been conducted concerning the burden of HIV infection and AIDS on the older adults in the Northwest Region of Cameroon (...) . Using in-depth interviews (IDIs) and focus group discussions (FGDs), data were collected from 36 participants who were purposively selected from the three divisions which had been chosen randomly. 6 FGD sessions were held with 30 women aged 60 years and above and who were affected by HIV infection and AIDS, while IDIs sessions were held with 6 male community leaders. The results revealed that HIV infection and AIDS has added another dimension to the role of older persons. HIV infection and AIDS

2018 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance

190. Longitudinal analysis of HIV risk behaviour patterns and their predictors among public primary care patients with tuberculosis in South Africa Full Text available with Trip Pro

Longitudinal analysis of HIV risk behaviour patterns and their predictors among public primary care patients with tuberculosis in South Africa The goal of this study was to identify various HIV risk behaviours among tuberculosis (TB) patients in a longitudinal study design in South Africa. In 42 public primary healthcare facilities in three districts in three provinces, adult new TB and TB retreatment patients with hazardous or harmful alcohol use were interviewed within 1 month of initiation (...) of anti-TB treatment and were followed up at 6 months. The total sample with a complete 6-month follow-up assessment was 853. At the follow-up assessment, several HIV risk behaviours significantly reduced from baseline to follow-up. In multivariate Generalized Estimating Equations logistic regression analyses, high poverty (odds ratio (OR): 2.68, 95% confidence interval (CI): 1.56-4.62), Posttraumatic Stress Disorder (PTSD) symptoms (OR = 1.55, 95% CI = 1.03-2.36), and sexual partner on antiretroviral

2018 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance

191. Accounting for youth audiences’ resistances to HIV and AIDS messages in the television drama Tsha Tsha in South Africa Full Text available with Trip Pro

Accounting for youth audiences’ resistances to HIV and AIDS messages in the television drama Tsha Tsha in South Africa Theoretical debates and literature on E-E efforts in Africa have largely focussed on understanding how and why interventions on HIV and AIDS are effective in influencing behaviour change among target communities. Very few studies have sought to investigate and understand why a substantial number of targeted audiences resist the preferred readings that are encoded into E-E (...) interventions on HIV and AIDS. Using cultural studies as its conceptual framework and reception analysis as its methodology, this study investigated and accounted for the oppositional readings that subaltern black South African youths negotiate from Tsha Tsha, an E-E television drama on HIV and AIDS in South Africa. Results from the study show that HIV and AIDS messages in Tsha Tsha face substantial resistances from situated youth viewers whose social contexts of consumption, shared identities, quotidian

2018 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance

192. Darunavir Krka - HIV

Active Substance Master File = Drug Master File BCS Biopharmaceutics Classification System BP British Pharmacopoeia CoA Certificate of Analysis COBI cobicistat CRS Chemical Reference Substance (official standard) DAD Diode array detector DP Decentralised (Application) Procedure DRV darunavir DSC Differential Scanning Calorimetry EC European Commission GC Gas Chromatography HDPE High Density Polyethylene HIV human immunodeficiency virus HPLC High Pressure Liquid Chromatography IPC In-process control (...) Krka, co-administered with low dose ritonavir or other pharmacokinetic enhancer is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection. Darunavir Krka 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: - antiretroviral therapy (ART)-naïve (see

2018 European Medicines Agency - EPARs

193. Darunavir Krka d.d. - HIV

Active Substance Master File = Drug Master File BCS Biopharmaceutics Classification System BP British Pharmacopoeia CoA Certificate of Analysis COBI cobicistat CRS Chemical Reference Substance (official standard) DAD Diode array detector DP Decentralised (Application) Procedure DRV darunavir DSC Differential Scanning Calorimetry EC European Commission GC Gas Chromatography HDPE High Density Polyethylene HIV human immunodeficiency virus HPLC High Pressure Liquid Chromatography IPC In-process control (...) enhancer is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection (see section 4.2). Darunavir Krka d.d. 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: - antiretroviral therapy (ART)-naïve (see section 4.2). - ART-experienced with no darunavir

2018 European Medicines Agency - EPARs

194. [Dolutegravir (HIV infection) - addendum to commission A17-11]

Infections; HIV-1; Heterocyclic Compounds, 3-Ring; Humans; dolutegravir Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32017000408 Date abstract record published 06/11/2017 Health Technology Assessment (HTA) database Copyright © 2019 Institut fuer Qualitaet (...) [Dolutegravir (HIV infection) - addendum to commission A17-11] Dolutegravir (HIV-infektion): addendum zum auftrag A17-11; auftrag A17-37 [Dolutegravir (HIV infection) - addendum to commission A17-11] Dolutegravir (HIV-infektion): addendum zum auftrag A17-11; auftrag A17-37 [Dolutegravir (HIV infection) - addendum to commission A17-11] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from

2018 Health Technology Assessment (HTA) Database.

195. [Darunavir-cobicistat-emtricitabine-tenofovir alafenamide (HIV infection) - benefit assessment according to õ35a Social Code Book V]

; Emtricitabine; HIV Infections; Humans; Tenofovir; emtricitabine tenofovir alafenamide Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32018000047 Date abstract record published 06/02/2018 Health Technology Assessment (HTA) database Copyright © 2019 Institut (...) [Darunavir-cobicistat-emtricitabine-tenofovir alafenamide (HIV infection) - benefit assessment according to õ35a Social Code Book V] Darunavir/cobicistat/emtricitabin/tenofoviralafenamid (HIV-infektion): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-48 [Darunavir-cobicistat-emtricitabine-tenofovir alafenamide (HIV infection) - benefit assessment according to §35a Social Code Book V] Darunavir/cobicistat/emtricitabin/tenofoviralafenamid (HIV-infektion): nutzenbewertung gemäß

2018 Health Technology Assessment (HTA) Database.

196. Effect of an interactive text-messaging service on patient retention during the first year of HIV care in Kenya (WelTel Retain): an open-label, randomised parallel-group study Full Text available with Trip Pro

Effect of an interactive text-messaging service on patient retention during the first year of HIV care in Kenya (WelTel Retain): an open-label, randomised parallel-group study Retention of patients in HIV care is crucial to ensure timely treatment initiation, viral suppression, and to avert AIDS-related deaths. We did a randomised trial to determine whether a text-messaging intervention improved retention during the first year of HIV care.This unmasked, randomised parallel-group study was done (...) at two clinics in informal settlements in Nairobi, Kenya. Eligible participants were aged 18 years or older, HIV-positive, had their own mobile phone or access to one, and were able to use simple text messaging (or have somebody who could text message on their behalf). Participants were randomly assigned (1:1), with random block sizes of 2, 4, and 6, to the intervention or control group. Participants in the intervention group received a weekly text message from the automated WelTel service for 1 year

2018 The Lancet. Public health Controlled trial quality: predicted high

197. Delivering comprehensive HIV services across the HIV care continuum: a comparative analysis of survival and progress towards 90-90-90 in rural Malawi Full Text available with Trip Pro

Delivering comprehensive HIV services across the HIV care continuum: a comparative analysis of survival and progress towards 90-90-90 in rural Malawi Partners In Health and the Malawi Ministry of Health collaborate on comprehensive HIV services in Neno, Malawi, featuring community health workers, interventions addressing social determinants of health and health systems strengthening. We conducted an observational study to describe the HIV care continuum in Neno and to compare facility-level HIV (...) outcomes against health facilities nationally.We compared facility-level outcomes in Neno (n=13) with all other districts (n=682) from 2013 to 2015 using mixed-effects linear regression modelling. We selected four outcomes that are practically useful and roughly mapped on to the 90-90-90 targets: facility-based HIV screenings relative to population, new antiretroviral therapy (ART)enrolments relative to population, 1-year survival rates and per cent retained in care at 1 year.In 2013, the average

2018 BMJ global health

198. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. (Abstract)

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lifelong HIV antiretroviral therapy (ART) has prompted an interest in two-drug regimens to minimise cumulative drug exposure and toxicities. The safety, tolerability, and efficacy of dolutegravir and rilpivirine suggest potential compatibility and effectiveness as a two-drug regimen. We aimed (...) to investigate this two-drug regimen in a phase 3 study.We identically designed SWORD-1 and SWORD-2, which were open-label, parallel-group, multicentre, phase 3, randomised, non-inferiority studies in 12 countries evaluating efficacy and safety of once-daily dolutegravir 50 mg plus rilpivirine 25 mg versus current ART regimen (CAR). We included participants aged 18 years or older who were on first or second ART with stable plasma HIV-1 RNA (viral load <50 copies per mL) for 6 months or longer at screening

2018 Lancet Controlled trial quality: predicted high

199. HIV and the menopause

HIV and the menopause BRITISH MENOPAUSE SOCIETY T ool for clinicians Information for GPs and other health professionals 1 of 2 HIV and the menopause Introduction Over the past two decades, antiretroviral therapy (ART) has transformed HIV into a long-term condition with normal life expectancy for people stable on treatment. In 2016, 10,350 women living with HIV aged 45-56 (the age when women usually go through the menopause) attended HIV clinics in the UK. This is nearly half of all women (...) attending for HIV care in the UK, and is five times the number in 2006 1 . As the number of women living with HIV reaching their midlife grows, we are beginning to understand the importance of addressing their healthcare needs during the menopause. What is the impact of the menopause on women living with HIV? • The menopause transition can have multi-dimensional impacts on the health and well-being of women living with HIV. • There is conflicting evidence on the association between HIV and earlier age

2018 British Menopause Society

200. Vaccination of HIV infected children

– 13-valent pneumococcal conjugate vaccine Hib/MenC - Haemophilus influenzae type b and Neisseria meningitidis capsular group C conjugate vaccine MenC - meningococcal capsular group C conjugate vaccine 4CMenB – multicomponent meningococcal capsular group B protein vaccine LAIV – live attenuate influenza vaccine MMR – measles, mumps, rubella vaccine HPV – human papilloma virus vaccine MenACWY – quadrivalent meningococcal capsular groups A, C, W and Y conjugate vaccine Hep A&B – combined hepatitis (...) Vaccination of HIV infected children Vaccination of HIV infected children (UK schedule, 2018) Abbreviation list DTaP/IPV/Hib – diphtheria/tetanus/acellular pertussis/inactivated polio vaccine/ Haemophilus influenzae type b DTaP/IPV or dTaP/IPV - diphtheria/tetanus/acellular pertussis/inactivated polio vaccine “D” - vaccines containing the higher dose of diphtheria toxoid (contain not less than 30IU) “d” - vaccines containing the lower dose of diphtheria toxoid (contain approximately 2IU) PCV13

2018 The Children's HIV Association